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Infective endocarditis in dialysis patients: New challenges and
old.
Background. Since the 1960s chronic hemodialysis (HD) has
been recognized as a risk factor for the development of infective
endocarditis (IE). Historically, it has been particularly associated
with vascular access via dual lumen catheters. We wished to
examine the risk factors for, and consequences of, IE in the
modern dialysis era.
Methods. Cases of IE (using the Duke criteria) at St. Thomas’
Hospital (1980 to 1995), Guy’s (1995 to 2002), and King’s College
Hospitals (1996 to 2002) were reviewed.
Results. Twenty-eight patients were identified as having de-
veloped IE (30 episodes of IE). Twenty-seven patients were
on long-term HD and one patient was on peritoneal dialysis
(PD). Mean age was 54.1 years, and mean duration of HD prior
to IE was 46.3 months. Eight patients were diabetic. Primary
HD hemoaccess was an arteriovenous fistula (AVF) in 41.3%,
a dual-lumen tunneled catheter (DLTC) in 37.9%, a polytetra-
fluoroethylene (PTFE) graft in 10.3%, and a dual- lumen non-
tunneled catheter (DLNTC) in 4%. The presumed source of
sepsis was directly related to hemoaccess in 25 HD patients:
DLTC in 48%; AVF in 32%; PTFE in 12%; and DLNTC
in 4%. Staphylococcus aureus [including methicillin resistant
Staphylococcus aureus (MRSA)] was present in 63.3%. The
mitral valve was affected in 41.4% of patients, aortic valve in
37.9% of patients, and both valves were affected in 17.2% of
patients. Of note, 51.7% of patients had an abnormal valve
before the episode of IE. In 15 cases surgery was undertaken.
Fourteen patients survived to discharge, and 12 survived for
30 days. In 15 cases antibiotic treatment alone was employed;
in this case, eight patients died and seven survived to discharge.
Conclusion. This is the largest reported confirmed IE series
in dialysis patients. Infective endocarditis in HD patients re-
mains a challenging problem—although hemoaccess via dual-
lumen catheters remains a significant risk, many cases devel-
oped in patients with AVFs and this group suffered the greatest
mortality. An abnormal valve (frequently calcified) was an-
other risk factor; because valve calcification is now common
after 5 years on dialysis, more effort in preventing this avoid-
able form of ectopic calcification may reduce the risk of devel-
oping IE.
Key words: endocarditis, hemodialysis, vascular access, calcification,
valve lesions.
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Infective endocarditis (IE) has been recognized as a
complication of hemodialysis since 1966 [1]. Five previ-
ous series have addressed this problem [2–6] (Table 1).
The incidence of bacteremia in hemodialysis patients has
been reported as ranging from 0.7 to 1.2 episodes per
100 patient months [7–9]. Bacteremia rates are highest
in patients dialyzing through dual-lumen tunneled cathe-
ters (DLTC) [10, 11], ranging from 1.3 to 5.5 episodes
per 1000 catheter days (equivalent to 3.9 to 16.7 episodes
per 100 patient months). The incidence of bacteremia is
lower in those patients whose form of hemoaccess is a
synthetic polytetrafluoroethylene (PTFE) graft or native
arteriovenous fistula (AVF). In one study, the relative
risk of bacteremia was 7.64, 1.29, and 1.0 for DLTCs,
PTFE grafts, and AVFs, respectively [11, 12]. Minga et
al [13] demonstrated a bacteremia rate in patients whose
form of access was a PTFE graft of 8.2 infections per 100
graft years (equivalent to 0.68 episodes per 100 patient
months). The Canadian Hemodialysis morbidity study
demonstrated a probability of access infection at 12
months of 4.5% for AVFs and 19.7% for PTFE grafts
(relative risk, 3.41; P  0.0002) [14].
The incidence of IE complicating bacteremic episodes
in hemodialysis patients is 1.1% to 12% [8–11, 13]. The
overall incidence is low—10 episodes of IE per 223,358
(0.0045%) hemodialysis treatments delivered in one study
[6]—but significantly higher than in a nondialysis popula-
tion. Community-acquired native valve IE occurs with
an incidence of 1.7 to 4.45 episodes per 100,000 person
years, and nosocomial native valve IE occurs at a rate
of 0.94 episodes per 100,000 person years [15]. The study
by Strom et al [16] put the relative risk of IE in dialysis
patients over that of the general population at 16.9.
Moreover, the mortality of IE in a hemodialysis popula-
tion is high: approximately 30% deaths occurred during
initial hospitalization of 30 days in previously published
series [3–6]. This is in contrast to a nondialysis popula-
tion, in which a 90% to 95% cure rate would be expected
within 28 days of antibiotic treatment [17–19].
All of the previously published series of IE in hemodi-
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Table 1. Previously published series on IE in hemodialysis patients
Leonard, Leopold, McCarthy and Guy’s King’s
Cross and and Shapiro [3] Takahashi et al [4] Robinson et al [5] Steckelberg [6] Thomas’ data
Steigbigel [2]a 1966–1972 1985–1989 1990–1997 1983–1997 1980–2002
Episodes of IE in series (N ) 33 9 19 20 20 30
Gender (male) % 62 (NS in 11) 67 ? 30 76 60.7
Mean age years 45 (NS in 11) 55 ? 55 63 54.1
Diabetics % NS — ? 45 35 28.5
Route of hemoaccess %
Shunt/cannula 23b 67 — — — —
PTFE graft — 33 — 5 10 10.8
AVF 15b — 40 45 70 41.3
Catheter — — 60 55 20 41.3
Other — — — — — 7.8
Duration of hemodialysis prior
to episode of IE months 20.3 28.6 19.5 NS 2420.5 46.3
Organism causing IE %
Staphylococcus aureus 47 56 75 60 40 63.3
Staph. Epidermidis/CNS 3 11 25 10 13.3
Enterococcus sp. 13 11 10 20 10
Other streptococci 20 — — 25 10
Other 13 18 10 5 3.4
Heart valve involved %
Aortic valve 62 33 31 30 15 36.6
Mitral valve 26 11 42 50 45 43.3
Tricuspid valve 6 11 25 10 0
1 valve 6 44 15 10 16.7
Preexisting valve lesion or
previous valve surgery % NS 78 32 NS 90 50
Requirement for valve
replacement or repair % 39 11 ? 25 30 50
Outcomes %
Survival to 30 days from
diagnosis of IE NS 67 ? NS 71 73
Death during initial hospital
admission NS 33 68.4 30 NS 30
Abbreviations are: PTFE, polytetrafluoroethylene; AVC, arteriovenous cannula; AVF, arteriovenous fistula; NS, not stated.
a Includes 9 patients reported by Leonard, Leopold, and Shapiro [3]
b Three patients had both AVC and AVF
alysis patients have originated from institutions in the
United States or South America. The nature of hemoac-
cess in Europe is different, with a far greater proportion
of patients receiving dialysis through AVFs: 80% Euro-
pean patients vs. 24% of United States prevalent patients
[20]. In the United States, approximately 60% of patients
dialyze via PTFE grafts [20, 21]. At King’s College Hos-
pital approximately 66% of patients dialyzed through
AVFs, 18% through tunneled cuffed catheters, 9% through
PTFE grafts, and 7% through non-tunneled temporary
lines (unpublished data, 2000).
This paper will first review the findings of the pre-
viously published series (Table 1) and subsequently pres-
ent data on 30 episodes of IE in chronic dialysis patients,
including one episode in a patient on continuous ambula-
tory peritoneal dialysis (CAPD) receiving treatment at
two institutions in the United Kingdom.
METHODS
Chronic dialysis patients (hemodialysis for a minimum
of 90 days) with IE were retrospectively identified from
searches of the Endocarditis Database at St. Thomas’
Hospital (1980 to 1995), the Bacteremia Database cross
referenced with the Renal Unit database at Guy’s Hospi-
tal (1995 to 2002), and the Renal Unit Database at King’s
College Hospital (1995 to 2002). All patients had end-
stage renal failure (ESRF) and were receiving regular
(90 days) hemodialysis prior to the onset of the episode
of IE. Patients were included if they met the Duke crite-
ria for definite or possible IE (Table 2) [22]. Patients with
acute or chronic renal failure who required hemodialysis
during an episode of IE were excluded from the analysis.
Case notes, operation notes, and laboratory and au-
topsy reports were reviewed for each patient to extract
demographic information, clinical data, and clinical out-
come. Demographic data collected included age, sex,
cause of renal failure, duration of dialysis prior to episode
of IE, the route of hemoaccess, and the presence of
any preexisting valve lesion or previous valve surgery.
Clinical data included clinical findings and laboratory
investigation results at the time of presentation, the
proven or suspected portal of entry for the causative
organism, the organism causing the episode of IE, the
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Table 2. Duke University criteria for the diagnosis of infective endocarditis
Definite Infective Endocarditi
Pathologic Criteria
Microorganisms: demonstrated by culture or histology in a vegetation, or in a vegetation that has embolized, or in an intracardiac abscess or
Pathologic lesions: vegetation or intracardiac abscess present, confirmed by histology showing active endocarditis
Clinical criteria—using definitions listed below
2 major criteria, or
1 major and 3 minor criteria, or
5 minor criteria
Possible infective endocarditis
1 major criteria and 1 minor criteria, or
3 minor criteria
Rejected
Firm alternative diagnosis for manifestations of endocarditis, or
Resolution of manifestations of endocarditis, with antibiotic therapy for 4 days or less, or
No pathologic evidence of infective endocarditis at surgery or autopsy after antibiotic therapy for 4 days or less
Major criteria
Positive blood culture for infective endocarditis
Typical microorganism for infective endocarditis from two separate blood cultures: Viridans streptococci, Streptococcus bovis, HACEKa
group, Staphylococcus aureus or enterococci
Persistently positive blood culture, defined as recovery of a microorganism consistent with infective endocarditis from
Blood cultures drawn more than 12 hours apart or
All of three or a majority of four or more separate blood cultures, with the first and last drawn at least 1 hour apart
Evidence of endocardial involvement
Positive echocardiogram for infective endocarditis [TEE recommended in patients with prosthetic valves, rated at least “possible IE” by clinical
criteria, or complicated IE (paravalvular abscess); TTE as first test in other patients], defined as follows
Oscillating intracardiac mass, on valve or supporting structures, or in the path of regurgitant jets, or on implanted material, in the absence
of an alternative anatomic explanation, or
Abscess, or
New partial dehiscence of prosthetic valve, or
New valvular regurgitation (increase or change in preexisting murmur not sufficient)
Evidence of Q fever infection
Single positive blood culture for Coxiella burnetti OR antiphase 1 IgG antibody titre 1:800
Minor criteria
Predisposition: predisposing heart condition or intravenous drug use
Fever 38C
Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages,
Janeway lesions
Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth spots, rheumatoid factor
Microbiologic evidence: positive blood culture but not meeting major criterion as noted previously,b or serologic evidence of active infection
with organism consistent with infective endocarditis
a HACEK group, Haemophilus spp., Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella spp., and Kingella kingae
b Excluding single positive cultures for coagulase-negative Staphylococci and organisms that do not cause endocarditis
duration and type of antibiotic therapy administered, and
echocardiographic findings. Clinical outcomes recorded
were survival and requirement for valve surgery. Figures
1 through 6 show examples from endocarditis patients
in this series.
RESULTS
Patient demographics
Thirty episodes of IE occurred in 28 patients. Seven-
teen patients (60.7%) were male. The mean age was 54.1
years (range, 22 to 81 years). Eight cases occurred at St
Thomas’ between 1970 and 1995 (when the unit merged
with Guy’s). Fifteen cases (13 patients) occurred at
Guy’s, and seven at King’s College, between 1995 and
2002. In the case of Guy’s, in the period between 1995
and 2002, there were 479 patients accepted into long-
term (90 days) HD, which equates to a prevalence of
13/479 patients (i.e., 2.7% of patients). In terms of epi-
sodes of IE per dialysis treatment delivered, this is 15/
26,9007, or 0.0056%. The value for King’s was similar
(data not shown).
Clinical data
Eight patients (28.5%) had diabetes as a cause of their
ESRF, 8 (28.5%) had a chronic or rapidly progressive
glomerulonephritis, 5 (17.8%) had adult polycystic kid-
ney disease, 1 (3.3%) had hypertensive nephropathy, and
2 had other causes of renal failure. The cause of renal
failure was unknown in 4 patients.
The principal mode of dialysis access at the time of
each episode of IE was as follows: AVF, 41.3%; DLTC,
37.9%; PTFE graft, 10.8%; DLNTC, 3.4%; Tenchkoff
catheter, 3.4%; and unknown, 3.4%. The mean length
of time from starting dialysis to the episode of IE was
46.3 months (range, 1.5 to 180 months).
The definite or presumed source of bacteremia causing
each episode of IE was related to dialysis access in 26
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Table 3. Organisms cultured from blood for each episode of IE
Organism Episodes of IE %
Staphylococcus aureus 17 (56.7%)
Staphylococcus epidermidis/coagulase
negative staphylococci 4 (13.3%)
Enterococci 3 (10.0%)
Other Streptococci 3 (10.0%)
MRSA 2 (6.6%)
Others/unknown 1 (3.4%)
MRSA is methicillin-resistant Staphylococcus aureus.
episodes. Of these, 12 (46%) were due to DLTC infec-
tions, 8 (27%) were related to AVFs, 3 (10%) to PTFE
grafts, 1 (3%) to a DLNTC, and 1 (3%) to a Tenchkoff
catheter. The PD patient in whom the Tenchkoff cathe-
ter was used had a history of Staphylococcal exit site
infections. Four episodes of bacteremia were thought to
be unrelated to dialysis access.
Embolic phenomena were relatively rare (5 patients).
One patient’s endocarditis was diagnosed after a septic
embolus lodged in a popliteal artery, producing distal
gangrene. Another patient lost an arm from a septic
embolus to the brachial artery. Two patients suffered
cerebral infarctions.
Microbiologic data
Staphylococcus aureus [including methicillin resistant
Staphylococcus aureus (MRSA)] was the predominant
organism [19 episodes (63.3%)] causing IE, responsible
for 17 episodes (56.7%) for non-MRSA and two episodes
(6.6%) for MRSA. The other cultured organisms are
listed in Table 3.
The mitral valve was the most commonly affected
valve (13 episodes, 43.3%). The aortic valve was affected
in 11 episodes (36.6%), and both the aortic and mitral
valve were affected in 5 episodes (16.7%). In one case
the affected valve was unknown.
Echocardiography
Echocardiographic data were available for 27/30 epi-
sodes. Both transthoracic echocardiography (TTE) and
transesophageal echocardiography (TEE) were employed
in the investigation of 14 episodes (48%). TTE alone
was used in 12 episodes (41.4%) and TEE alone in 1
episode. No echocardiography was performed in 3 epi-
sodes; the diagnosis of IE was made at post-mortem in
two of these episodes, the patients having died 2 and 6
days after presentation, respectively. In the third episode
the diagnosis was made on the basis of a new murmur
and was classified as a definite case of IE according to
the Duke criteria.
Conclusive diagnostic information (satisfying the
Duke criteria for echocardiographic evidence of IE) [22]
was provided by TTE in 14 episodes (48.3%). TEE was
required to confirm the clinical suspicion of IE in 5 epi-
sodes (17.2%), and provided additional clinically useful
information in 1 episode. Prior TTE had been under-
taken in 5 of these cases and had been nondiagnostic.
No diagnostic features of IE were present on TTE or
TEE in 5 episodes (including one patient who had only
a TTE, which was normal, and one patient who refused
TEE). Of these, 4 patients subsequently had histologic
evidence of IE at surgery or autopsy.
Data for left ventricular (LV) function at the time of
diagnosis of IE are incomplete (20/27 cases) but show
normal LV function (ejection fraction 50%) in 8 and
impaired LV function in 12 reports.
Outcome data
Fifteen patients underwent valve replacement or re-
pair following an episode of IE; mortality data for this
group is compared to those managed with antibiotics
alone in Table 4. Mortality during the initial hospital
admission for IE was 31% overall. Further outcome data
are provided in Table 5. With the small numbers we
could not discern a center effect. Comparing subjects
with onset of dialysis prior to 1985 to those in whom
dialysis first began after 1985, there was no difference
in age at start of dialysis or in survival.
DISCUSSION
Twelve (40%) of the patients in our series had an
AVF as their main form of dialysis access, and of these
patients, the AVF was the definite or suspected portal
of entry for the causative organism in eight IE episodes
(26.6%). Our presumption that the AVF was the source
of bacteremia in these episodes is supported by the fact
that the causative organism in 7 episodes was a skin
commensural (Staphylococcus aureus in 6 and Staphylo-
coccus epidermidis in 1). This finding is in contrast with
the experience of McCarthy and Steckelberg [6], who
implicated an AVF in only 1 out of 13 episodes of IE
caused by an infected hemoaccess. They argued that
unless there is a visible sign of infection in the AVF, the
occurrence of IE in a hemodialysis patient with an AVF
should prompt examination for another portal of entry
of infection. We would recommend that an AVF not be
overlooked as a possible source of bacteremia in IE,
even if it does not appear infected. It is obviously difficult
to ascribe a causative infective role to an AVF without
obvious physical signs of infection and to a considerable
extent this remains a diagnosis of exclusion.
We report one episode of endocarditis presumed to
be due to an infected peritoneal dialysis (PD) catheter.
To our knowledge this occurrence has been reported
just once before [23].
As in previous series, Staphylococcus aureus was the
most common causative organism, accounting for 63.3%
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Table 4. Comparison of outcomes for patients undergoing valve repair or replacement vs. non-surgically managed patients
Surgical management (N  15)
12 valve replacement; Nonsurgical management
2 valve repair; 1 unsuccessful (N  15)
Died during initial hospital admission 1 (6.9%) 8 (53.3%)b
Survival to discharge 14 (93.3%) 7 (46.6%)
Survival to 30 days (from admission) 12 (80%)a 7 (46.6%)c
aExcludes 2 patients discharged back to the referring hospital at 30 days’ post-admission, and subsequently lost to follow up
bMean duration of hospital admission prior to death was 14.9 days (range, 2 to 43 days)
cExcludes 2 patients lost to follow up
Table 5. Overall outcome data for all episodes of IE (N  30)
Episodes %
Died during initial hospital admission 9 (30%)
Survival to discharge (from time of admission
with episode of IE) 21 (70%)
Survival to 30 days (from time of admission with
episode of IE)a 19 (73%)
Survival to 1 year (or alive at most recent
follow-up)b 12 (54.5%)
aExcludes 4 patients who were lost to follow up
bExcludes 8 patients who were lost to follow up
Fig. 1. Postmortem aortic valve showing calcification of aortic valve
cusps (arrow).
Fig. 2. CT of the thorax showing extreme mitral valve calcification (arrow).
Fig. 3. Upper, transesophageal echocardiogram showing mitral valve
vegetation (arrow). Lower, mitral valve vegetation at surgery (arrow).
of all IE episodes, including 2 with MRSA. In the United
States there is much more MRSA, and empiric therapy
would, by necessity, need to cater to this possibility.
Similarly, the mitral valve was most commonly affected.
Previously damaged cardiac valves, as determined by
clinical or echocardiographic findings, were present in
13 IE episodes (Fig. 2); in addition, two more episodes
involved prosthetic valves. The true prevalence of valvu-
lar damage is probably much higher than our findings
would suggest [24], and the increased frequency of hemo-
dynamically significant aortic and mitral valvular changes
in hemodialysis patients is well recognized [7]. The study
by Abbott et al [25] showed that there was at least a
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Fig. 4. Aortic valve remnant (destroyed by Staphylococcus) removed
from a patient.
Fig. 5. Intraoperative view of perforation between right atrium and
left ventricle (surgical forceps and arrows).
five-fold increased relative risk of valvular heart disease
in dialysis cohorts compared to the general population,
and this risk increased with dialysis vintage. The preva-
lence of cardiac valvular calcification, in particular, is
significantly more common in chronic hemodialysis pa-
tients than in a nondialysis population [7] and correlates
with duration of time on hemodialysis, metabolic de-
rangements of calcium-phosphate and parathyroid hor-
mone (PTH), and the chronic micro-inflammatory milieu
of uremia [26–28]. Given that rates of acceptance into
hemodialysis are increasing (including a higher propor-
tion of older patients in whom valvular calcification is
virtually ubiquitous), and along with improved survival
in hemodialysis patients, one would expect the incidence
of IE in dialysis patients to increase with significant impli-
cations for the investigation and treatment of these pa-
tients, in particular cardiac, diagnostic, and surgical ex-
pertise. Whether in the emergency or elective setting,
mortality rates of major cardiac surgery in dialysis pa-
Fig. 6. Gram stain of surgical resection/postmortem material from mi-
tral valve.
tients are considerably higher than those reported in non-
uremic cohorts [7].
The superior sensitivity of TEE over TTE in confirm-
ing the clinical diagnosis of IE is well recognized [29, 30].
In our series the sensitivity of TTE for the identification
of definite vegetations was 57.7%. TEE alone was diag-
nostic or provided further clinically important informa-
tion in 6 episodes, emphasizing the importance of this
investigation in dialysis patients with suspected IE [31].
Only 18 out of 30 episodes of IE were classified as
“definite” according to the Duke criteria (Table 2) [22].
In a patient with S. aureus or enterococcal bacteremia,
the presence of an alternative source for such organisms,
for example a dual-lumen tunneled catheter, PTFE graft,
or AVF specifically excludes the presence of these organ-
isms in blood culture as a major criteria according to
Duke. In the absence of this exclusion another 6 patients
in our series would have been classified as “definite.”
The limitations of the Duke criteria in this respect have
been discussed elsewhere [5, 6].
Fifteen patients underwent cardiac valve replacement
or repair; 14 survived to hospital discharge (the 15th died
after resection of affected cardiac tissue left an unviable
cardiac remnant). This is in contrast with the outcomes
reported in other series [3–6]. The improved outcomes
in patients managed surgically presumably reflect appro-
priate selection of this group.
Sixty-six percent of patients that died during their ini-
tial admission dialyzed through a “nonremovable” dial-
ysis access device (e.g., AVF or PTFE graft). However,
such methods of hemoaccess constituted only 44% of
the total in which the route of hemoaccess was consid-
ered the portal of entry for the bacteremia. The difficulty
in removing infected PTFE grafts, or reluctance on the
part of clinicians to do so, may have resulted in increased
mortality in this group of patients. Robinson et al [5]
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reached similar conclusions regarding higher mortality
in patients dialyzing through PTFE grafts in their series.
The overall outcomes remain a cause for concern: in-
hospital mortality is over 30% and little more than 50%
of end-stage renal failure patients survive to one year
after an episode of IE. Despite advances in the diagnosis
and treatment of IE, the prognosis for this group of pa-
tients has not significantly improved since Leonard et al
[4] published the first series addressing this problem in
1973.
CONCLUSION
This series of 30 confirmed episodes of IE in end-stage
renal failure patients on regular dialysis is the largest to
date and confirms that this condition continues to carry
a high rate of mortality. Although dual-lumen tunneled
hemodialysis catheters are the most common source of
bacteremia resulting in infective endocarditis in dialysis
patients, AVFs and PTFE grafts are commonly impli-
cated and may be associated with higher mortality.
Prevention strategies which may further reduce the
future incidence of IE in long-term dialysis patients
should include scrupulous attention to asepsis in line
insertion and toileting, use of topical and intranasal mup-
irocin ointment to reduce Staphylococcal bacteremia
[32, 33], antibiotic locks in dialysis catheters [34], vaccina-
tion against Staphylococci (though uremic patients char-
acteristically respond poorly to immunization) [35], and
consideration of using antibiotic-impregnated DLTCs
when widely available [36]. A full economic analysis is
required, however, as the complication of IE is so rela-
tively rare, although these measures may also be ex-
pected to reduce bacteremias, which are much more
common. To date, the efficacy of antiseptic- and antibi-
otic-impregnated catheters has only been demonstrated
in triple-lumen nondialysis central venous catheters, al-
though trials of antibiotic-impregnated hemodialysis
catheters are being conducted.
Damaged, typically calcified, valves are another risk
factor for IE and the prevention of ectopic cardiac and
valvular calcification should be considered a priority [37].
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